FLUOROHMET (CITRATE) SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

FLUDEOXYGLUCOSE 18F

から入手可能:

CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION

ATCコード:

V09IX04

INN（国際名）:

FLUDEOXYGLUCOSE (18F)

投薬量:

157GBQ

医薬品形態:

SOLUTION

構図:

FLUDEOXYGLUCOSE 18F 157GBQ

投与経路:

INTRAVENOUS

パッケージ内のユニット:

100

処方タイプ:

Schedule C

治療領域:

ROENTGENOGRAPHY

製品概要:

Active ingredient group (AIG) number: 0152591019; AHFS: 36:68.00

認証ステータス:

APPROVED

承認日:

2016-06-06

製品の特徴

_ _
_[_
_18_
_F]Fluorodeoxyglucose, _
_18_
_F -FDG _
_Page 1 of 24_
PRODUCT MONOGRAPH
FLUOROHMET
([
18
F]Fluorodeoxyglucose,
18
F-FDG)
Solution for Injection, 45 - 4240 mCi per multi-dose vial
Diagnostic Radiopharmaceutical
University of Ottawa Heart Institute
National Cardiac PET Centre
40 Ruskin Street
Ottawa, ON K1Y 4W7
Date of Authorization:
December 29, 2010
NDS Control # 136101
_ _
_[_
_18_
_F]Fluorodeoxyglucose, _
_18_
_F -FDG _
_Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
DESCRIPTION....................................................................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................4
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS....................................................................................................7
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND
ADMINISTRATION................................................................................8
RADIATION
DOSIMETRY.............................................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND
STABILITY..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................13
DOSAGE FOR